| Mortalin: Protein partners, biological impacts, pathological roles, and therapeutic opportunities N Esfahanian, CD Knoblich, GA Bowman, K Rezvani Frontiers in Cell and Developmental Biology 11, 1028519, 2023 | 17 | 2023 |
| Treatment patterns and outcomes in KRASG12C‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center … SH Barghout, LJ Zhan, S Raptis, F Al-Agha, N Esfahanian, A Popovacki, ... Lung Cancer 194, 107898, 2024 | 4 | 2024 |
| Comprehensive analysis of proteasomal complexes in mouse brain regions detects ENO2 as a potential partner of the proteasome in the striatum N Esfahanian, M Nelson, R Autenried, JS Pattison, E Callegari, K Rezvani Cellular and molecular neurobiology 42 (7), 2305-2319, 2022 | 3 | 2022 |
| Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence N Esfahanian, SWS Chan, LJ Zhan, MC Brown, K Khan, J Lee, ... Cancer Treatment and Research Communications 37, 100774, 2023 | 1 | 2023 |
| EP12. 03-02 Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA) LJ Zhan, S Barghout, S Raptis, F Al-Agha, A Popovacki, N Esfahanian, ... Journal of Thoracic Oncology 18 (11), S680, 2023 | | 2023 |
| Clear Cell Carcinoma of Uterine Cervix: A Clinicopathologic Review and Molecular Characterization S Sanii, N Esfahanian, B Clarke, J Schwock, L Hogen, K Han, S Lheureux, ... LABORATORY INVESTIGATION 100 (SUPPL 1), 1129-1130, 2020 | | 2020 |
